 Links |
|
|
|
 |
 Videos |
|
|
|
|
 Blogs |
|
|
|
|
 News |
|
|
|
|
 Articles |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
Bookmark and share this category:
|
News
|
| |
|
| Canada OKs Osiris drug; first stem cell therapy |
BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient's body. ...
Rating: 0.00 (0 votes) |
|
|
|
| Canada OKs Osiris drug; first stem cell therapy |
BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient's body. ...
Rating: 0.00 (0 votes) |
|
|
| |
|
| Study unpicks gene changes behind breast cancer |
 LONDON (Reuters) - Scientists have mapped the complete genetic codes of 21 breast cancers and created a catalogue of the mutations that accumulate in breast cells, raising hopes that the disease may be able to be spotted earlier and treated more effectively in future. The research, the first of its kind, untangles the genetic history of how cancer evolves, allowing scientists to identify mutational patterns that fuel the growth of breast tumors, and start to work out the processes behind them. ...
Rating: 0.00 (0 votes) |
|
|
| |
| |
| |
|
| Onetime "King of Biotech" runs afoul of law again |
NEW YORK (Reuters) - David Blech, an investor who was known as the "King of Biotech" before he admitted to criminal charges of stock manipulation in 1998, has run into trouble with the law again over illegal trades in stocks of two biopharmaceutical companies. Blech told a federal judge in New York on Wednesday that in 2007 and 2008 he bought and sold stocks of Pluristem Therapeutics Inc and Intellect Neurosciences Inc in quick succession to try and conceal his own sales that might have reduced the stock's value. ...
Rating: 0.00 (0 votes) |
|
|
|
|
 Top Tags |
|
|
|
|
| Top Rated Links |
|
|
|
|
| Popular Links |
|
|
|
|
| Top Rated Videos |
|
|
|
|
| Popular Videos |
|
|
|
|
| Top Rated News |
|
|
|
|
| Popular News |
|
|
|
|
| Top Rated Articles |
|
|
|
|
| Popular Articles |
|
|
|
|
| In The News |
|
|
|
|
|
